3 news items
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
RYTM
3 Jun 24
practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international operations and the costs of any
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
RYTM
3 Jun 24
with the laws and regulations governing our international operations and the costs of any related compliance programs, the impact of competition, risks
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international
- Prev
- 1
- Next